Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sharpe, 23 are a HOLD (44.23%), 4 are a SELL (7.69%), 25 are a BUY (48.08%).
Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 87.36% that have a potential upside of 22.71% achieved within 242 days.
Matthew Sharpe’s has documented 119 price targets and ratings displayed on 12 stocks. The coverage is on Industrials, Technology sectors.
Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.
Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
$120
$0.41 (0.34%)
$140
13 days ago
(15-Apr-2025)
6/8 (75%)
$9.71 (8.80%)
123
Hold
$110
$-9.59 (-8.02%)
$155
14 days ago
(14-Apr-2025)
16/18 (88.89%)
$-2.03 (-1.81%)
121
Buy
$164
$44.41 (37.14%)
$171
2 months 2 days ago
(26-Feb-2025)
15/19 (78.95%)
$50.51 (44.51%)
180
Buy
$150
$30.41 (25.43%)
2 months 25 days ago
(03-Feb-2025)
7/8 (87.5%)
$20.59 (15.91%)
282
Hold
$140
$20.41 (17.07%)
$140
3 months 22 days ago
(06-Jan-2025)
11/11 (100%)
$9.26 (7.08%)
107
What Year was the first public recommendation made by Matthew Sharpe?